$RGC
Regencell Bioscience Holdings Ltd Stock $rgc

$rgc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 20-F Financial Statement

#000101376223007289 Filed on October 27, 2023

Income Statement

Concept	2023 Q2	2023	2022 Q2
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$4.692M	$2.562M
YoY Change		-8.1%	171.69%
% of Gross Profit
Research & Development		$1.582M	$1.397M
YoY Change		-37.04%	218.66%
% of Gross Profit
Depreciation & Amortization		$293.1K
YoY Change		95.23%
% of Gross Profit
Operating Expenses		$6.274M	$3.959M
YoY Change		-17.64%	186.59%
Operating Profit		-$6.274M
YoY Change		-17.64%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$210.0K	$23.13K
YoY Change		804.39%	-33.19%
Pretax Income		-$6.062M	-$3.936M
YoY Change		-20.18%	192.24%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$5.871M	-$3.854M
YoY Change		-22.69%	186.21%
Net Earnings / Revenue
Basic Earnings Per Share		$0.45
Diluted Earnings Per Share		-$0.45	-$301.0K
COMMON SHARES
Basic Shares Outstanding	13.01M shares	13.01M shares	13.01M shares
Diluted Shares Outstanding		13.01M shares

Balance Sheet

Concept	2023 Q2	2023	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$11.56M	$16.42M
YoY Change		-29.59%	27533.4%
Cash & Equivalents	$1.565M		$6.417M
Short-Term Investments		$10.00M	$10.00M
Other Short-Term Assets		$60.00K	$27.60K
YoY Change		117.39%	270.97%
Inventory
Prepaid Expenses	$56.55K		$27.60K
Receivables
Other Receivables
Total Short-Term Assets	$11.62M	$11.62M	$16.44M
YoY Change	-29.33%	-29.34%	24499.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$440.8K	$890.0K	$712.6K
YoY Change	-38.14%	-39.04%	770.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$110.0K	$114.3K
YoY Change		-3.76%	-40.29%
Total Long-Term Assets	$1.000M	$1.000M	$1.574M
YoY Change	-36.45%	-36.48%	476.08%
TOTAL ASSETS
Total Short-Term Assets	$11.62M	$11.62M	$16.44M
Total Long-Term Assets	$1.000M	$1.000M	$1.574M
Total Assets	$12.62M	$12.62M	$18.02M
YoY Change	-29.95%	-29.96%	5197.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$158.1K	$600.0K	$151.1K
YoY Change	4.6%	6.74%	-73.62%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$606.9K	$610.0K	$577.8K
YoY Change	5.05%	5.58%	-86.68%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$30.00K	$360.3K
YoY Change		-91.67%
Total Long-Term Liabilities		$30.00K	$360.3K
YoY Change		-91.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$606.9K	$610.0K	$577.8K
Total Long-Term Liabilities		$30.00K	$360.3K
Total Liabilities	$632.3K	$590.0K	$938.0K
YoY Change	-32.59%	-38.12%	-78.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.32M		-$11.44M
YoY Change	51.3%		186.24%
Common Stock	$29.43M		$130.00
YoY Change	22639943.85%		30.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.03M	$12.03M	$17.07M
YoY Change
Total Liabilities & Shareholders Equity	$12.62M	$12.62M	$18.02M
YoY Change	-29.95%	-29.96%	5197.66%

Cashflow Statement

Concept	2023	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.871M	-$3.854M
YoY Change	-22.69%	186.21%
Depreciation, Depletion And Amortization	$293.1K
YoY Change	95.23%
Cash From Operating Activities	-$4.963M
YoY Change	-5.77%
INVESTING ACTIVITIES
Capital Expenditures	$27.39K
YoY Change	-96.49%
Acquisitions
YoY Change
Other Investing Activities	$90.00K
YoY Change	-100.9%
Cash From Investing Activities	$58.98K
YoY Change	-100.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$134.9K
YoY Change	-99.4%
NET CHANGE
Cash From Operating Activities	-$4.963M
Cash From Investing Activities	$58.98K
Cash From Financing Activities	$134.9K
Net Change In Cash	-$4.852M
YoY Change	-176.32%
FREE CASH FLOW
Cash From Operating Activities	-$4.963M
Capital Expenditures	$27.39K
Free Cash Flow	-$4.990M
YoY Change	-17.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12805707	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10000000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.58
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40617
CY2023	dei	Entity Registrant Name EntityRegistrantName	REGENCELL BIOSCIENCE HOLDINGS LIMITED
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	9/F Chinachem Leighton Plaza
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	29 Leighton Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Causeway Bay
CY2023	dei	Entity Address Country EntityAddressCountry	HK
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, par value $0.00001
CY2023	dei	Trading Symbol TradingSymbol	RGC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13012866	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	5395
CY2023	dei	Auditor Name AuditorName	Marcum Asia CPAs LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023Q2	us-gaap	Cash Cash	1564795	usd
CY2022Q2	us-gaap	Cash Cash	6416998	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	10000000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	10000000	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	56548	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	27598	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11621343	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	16444596	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	440829	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	712594	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	108499	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	114302	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	451084	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	747426	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1000412	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1574322	usd
CY2023Q2	us-gaap	Assets Assets	12621755	usd
CY2022Q2	us-gaap	Assets Assets	18018918	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	7617770	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	158081	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	151127	usd
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	10570	usd
CY2022Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	15650	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	438263	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	410987	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	606914	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	577764	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25406	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	360268	usd
CY2023Q2	us-gaap	Liabilities Liabilities	632320	usd
CY2022Q2	us-gaap	Liabilities Liabilities	938032	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13012866	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13012866	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13012866	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13012866	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	130	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	130	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	29431927	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	28509304	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17315066	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11443936	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-86658	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12030333	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17065498	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-40898	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	15388	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11989435	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17080886	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12621755	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18018918	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	262664	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25275	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1576	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4429379	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5080341	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	941463	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1581628	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2512154	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	438323	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6273671	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1381362	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6273671	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	134913	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-6062329	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-86658	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-7617770	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1381362	usd
CY2023	us-gaap	Other Income OtherIncome	211342	usd
CY2022	us-gaap	Other Income OtherIncome	23215	usd
CY2021	us-gaap	Other Income OtherIncome	34617	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6062329	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7594555	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1346745	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-6062329	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7594555	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1346745	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5871130	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7445943	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1346745	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-191199	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-148612	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-6062329	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7594555	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1346745	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-86658	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6148987	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7594555	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1346745	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5957788	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7445943	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1346745	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	191199	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	148612	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6148987	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7594555	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1346745	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13012866	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.45
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2650892	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1346745	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3997637	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22200086	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	301085	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3250000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	2757907	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	164000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7594555	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17080886	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	922623	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11989435	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-6062329	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7594555	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1346745	usd
CY2023	us-gaap	Depreciation Depreciation	293135	usd
CY2022	us-gaap	Depreciation Depreciation	150147	usd
CY2021	us-gaap	Depreciation Depreciation	26456	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	476552	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	454250	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	922623	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2757907	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	85400	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	10733	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1415	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	28950	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	9429	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	7436	usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-5803	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	95196	usd
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	388	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6954	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-421863	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	477990	usd
CY2023	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-487672	usd
CY2022	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-430421	usd
CY2023	us-gaap	Increase Decrease In Due To Other Related Parties IncreaseDecreaseInDueToOtherRelatedParties	-5080	usd
CY2022	us-gaap	Increase Decrease In Due To Other Related Parties IncreaseDecreaseInDueToOtherRelatedParties	-67162	usd
CY2021	us-gaap	Increase Decrease In Due To Other Related Parties IncreaseDecreaseInDueToOtherRelatedParties	82812	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4962949	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5267055	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-767311	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27392	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	780876	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	970	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	10085400	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	10000000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	10000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58978	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10780876	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	172314	usd
CY2022	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-431969	usd
CY2021	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	612059	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	22673485	usd
CY2023	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	134913	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	164000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	134913	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22405516	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	439745	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-83145	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4852203	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6357585	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-327566	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6416998	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59413	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	386979	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1564795	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6416998	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59413	usd
CY2021	rgc	Conversion Of Shareholder Loan To Convertible Note Payable Related Party ConversionOfShareholderLoanToConvertibleNotePayableRelatedParty	3250000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	3250000	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	301085	usd
CY2022	rgc	Deferred Ipo Costs Transferred To Additional Paidin Capital DeferredIPOCostsTransferredToAdditionalPaidinCapital	172314	usd
CY2023	rgc	Rightofuse Assets Obtained In Exchange Of Lease Liabilities RightofuseAssetsObtainedInExchangeOfLeaseLiabilities	189767	usd
CY2022	rgc	Rightofuse Assets Obtained In Exchange Of Lease Liabilities RightofuseAssetsObtainedInExchangeOfLeaseLiabilities	1437069	usd
CY2023	rgc	Early Termination Of Rightofuse Assets In Exchange Of Lease Liabilities EarlyTerminationOfRightofuseAssetsInExchangeOfLeaseLiabilities	-40353	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 – Nature of business and organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) is a holding company incorporated as an exempted company on October 30, 2014, under the laws of the Cayman Islands and holding all of the outstanding share capital of Regencell Limited (Hong Kong), established under the laws of Hong Kong on November 20, 2014, and Regencell Bioscience Limited (Hong Kong), established under the laws of Hong Kong on May 12, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its controlling interests in the wholly owned subsidiaries, operates an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the global treatment of neurocognitive disorder and degeneration, specifically for Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”) and infectious diseases affecting people’s immune system such as COVID-19 (“COVID”). The Company is in the research and development stage and has not yet generated any revenue since inception.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2018, the Company entered into Strategic Partnership Agreement with Mr. Sik-Kee Au (the “TCM Practitioner”), the father of Mr. Yat-Gai Au, CEO and director of the Company. Pursuant to the Strategic Partnership Agreement, the Company has exclusive rights including the intellectual property rights and ownership of all his TCM formulae. Any inventions, TCM formulae, utilities, models’ improvements, research, discoveries, designs, processes, methods of manufacture, and products conceived or made by the TCM Practitioner in relation to TCM shall be the sole and exclusive property of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Strategic Partnership Agreement does not have a termination date and will remain effective indefinitely under the Hong Kong law. The Strategic Partnership Agreement can be amended or terminated by the mutual written agreement of the parties without breach. Pursuant to the Strategic Partnership Agreement, in exchange for the rights, the Company is required to donate three percent (3.0%) of net revenue that the Company generates in association with the use and/or commercialization of the TCM formulae to any of charitable institutions and/or trusts of a public character anywhere in the world at the sole and absolute choice of the TCM Practitioner and in such proportion at the sole and absolute discretion of the TCM practitioner on a yearly basis. The Company also undertakes to pay for all reasonable costs and expenses incurred by the TCM Practitioner in relation to the research and development of the TCM formulae for ADHD and ASD. All research and development costs and expenses incurred by the TCM Practitioner are charged to operations as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 20, 2021, the Company consummated its Initial Public Offering (“IPO”) of 2,300,000 Ordinary Shares at a price of $9.50 per share. The gross proceeds from IPO were approximately $21.85 million with net proceeds of approximately $19.82 million. As a result of the IPO, the Ordinary Shares now trade on the Nasdaq Capital Market under the symbol “RGC”. Additional net proceeds of approximately $2.85 million were received on August 20, 2021 from the issuance of the overallotment of 325,000 ordinary shares. 342,105 ordinary shares were issued to Mr. Yat-Gai Au upon the automatic conversion of $3,250,000 principal amount of the shareholder loan under the conversion note that was issued to Mr. Yat-Gai Au at a price of $9.50 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2021, Regencell Bioscience Limited entered into a joint venture agreement (the “JV Agreement”) with Honor Epic Enterprises Limited (“Honor Epic”), a company incorporated in the British Virgin Islands, to form a joint venture under the laws of Hong Kong (the “Joint Venture”). Pursuant to the JV Agreement, among other things and subject to the terms and conditions contained therein, Regencell Bioscience Limited and Honor Epic agreed to establish Regencell Bioscience Asia Limited (the “JV”), a private company limited by shares in Hong Kong.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the JV Agreement, Regencell Bioscience Limited shall contribute 60% of the capital for the JV to fund its operations including trading, manufacturing, marketing and distribution of traditional Chinese medicine formulae products and to procure, enable, provide or support the treatment of COVID-19. In addition, Regencell Bioscience Limited will grant the JV exclusive rights to market and distribute its proprietary COVID-19 TCM treatment (“Regencell COVID Treatment Products”) in ASEAN countries, India, Japan, Australia and New Zealand (“Designated Markets”), for an initial term of two years, pursuant to a license agreement to be entered into by and between Regencell Bioscience Limited and the JV. Honor Epic shall contribute 40% of the capital for the JV and shall use its best effort to market, promote, and distribute the Regencell COVID Treatment Products in the Designated Markets. Regencell Bioscience Limited may appoint two board members in the JV, and Honor Epic may appoint one board member in the JV. Sixty percent (60%) of the net profits or net loss of the JV will be distributed to or assigned to Regencell Bioscience Limited and the remaining forty percent (40%) being distributed to or assigned to Honor Epic. In the event that Regencell Bioscience Limited decides to dispose all of its shares in the JV, Regencell Bioscience Limited may require all other shareholders to sell and transfer all their shares in the JV to a proposed buyer, so long as Regencell Bioscience Limited is holding more than 50% of equity interest in the JV. Regencell Bioscience Limited is entitled to a right of first refusal if a shareholder receives a third-party offer to purchase the shares of the JV in accordance with the requirements specified in the JV Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has funded its operations primarily from the net proceeds from the completion of its IPO. The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Entity</b></span></td> <td style="width: 1%; text-align: center"> </td> <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Activities</b></span></td> <td style="width: 1%; text-align: center"> </td> <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place and Date of<br/> Incorporation</b></span></td> <td style="width: 1%; text-align: center"> </td> <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Bioscience Limited </span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development Day-to-day operations </span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, incorporated on May 12, 2015</span></td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by Regencell Bioscience Holdings Limited</span></td></tr> <tr style="vertical-align: top"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Limited </span></td> <td> </td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Production and testing laboratory Research and Development</p></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, incorporated on November 20, 2014</span></td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by Regencell Bioscience Holdings Limited</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Bioscience Asia Limited</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, incorporated on September 17, 2021</span></td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60% owned by Regencell Bioscience Limited </span></td></tr> <tr style="vertical-align: top"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Bioscience North America Limited</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BVI, incorporated on April 25, 2022</span></td> <td> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by Regencell Bioscience Holdings Limited</span></td></tr> </table>
CY2023	rgc	Net Revenue Percentage NetRevenuePercentage	0.03	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of estimates and assumptions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements required to be made by management include, but not limited to, the useful lives of property and equipment, impairment of long-lived assets, valuation of share options, share-based compensation, allowance for deferred tax assets and uncertain tax position. Actual results could differ from these estimates.</p>
CY2023	rgc	Cash Deposit CashDeposit	500000	hkd
CY2022	rgc	Cash Deposit CashDeposit	500000	hkd
CY2023	rgc	Cash Deposit CashDeposit	64000	usd
CY2022	rgc	Cash Deposit CashDeposit	64000	usd
CY2023	rgc	Leasehold Improvement LeaseholdImprovement	Shorter of the remaining lease terms or estimated useful lives
CY2023	us-gaap	Public Utilities Property Plant And Equipment Vehicles Useful Life PublicUtilitiesPropertyPlantAndEquipmentVehiclesUsefulLife	P5Y
CY2023	us-gaap	Advertising Expense AdvertisingExpense	300000	usd
CY2023Q2	us-gaap	Supplemental Unemployment Benefits Salary Continuation SupplementalUnemploymentBenefitsSalaryContinuation	25320	usd
CY2022Q2	us-gaap	Supplemental Unemployment Benefits Salary Continuation SupplementalUnemploymentBenefitsSalaryContinuation	29677	usd
CY2021Q2	us-gaap	Supplemental Unemployment Benefits Salary Continuation SupplementalUnemploymentBenefitsSalaryContinuation	14512	usd
CY2023	rgc	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Concentration of credit risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risks consist primarily of cash, the balances of which are stated on the consolidated balance sheets which represent the Company’s maximum exposure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash in good credit quality financial institutions in Hong Kong. The Company deposits its cash in financial institutions that it believes have high credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	916993	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	898713	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	476164	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	186119	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	440829	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	712594	usd
CY2023	us-gaap	Depreciation Depreciation	293135	usd
CY2022	us-gaap	Depreciation Depreciation	150147	usd
CY2021	us-gaap	Depreciation Depreciation	26456	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1415	usd
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3250000	usd
CY2021Q3	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	342105	shares
CY2023Q2	us-gaap	Accrued Rent Current And Noncurrent AccruedRentCurrentAndNoncurrent	4103	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	24615	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	49230	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Deferred RelatedPartyTaxExpenseDueToAffiliatesDeferred	600000	usd
CY2022	us-gaap	Related Party Tax Expense Due To Affiliates Deferred RelatedPartyTaxExpenseDueToAffiliatesDeferred	300000	usd
CY2021Q1	us-gaap	Debt Current DebtCurrent	3000000	usd
CY2021Q1	rgc	Promissory Note Principal Amount PromissoryNotePrincipalAmount	3250000	usd
CY2021Q3	rgc	Promissory Notes PromissoryNotes	342105	shares
CY2021Q3	rgc	Ordinary Price OrdinaryPrice	9.5
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	431969	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.165	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.165	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.165	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.165	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.165	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.165	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.165	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.165	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.165	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2305767	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1457716	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	659669	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	607288	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	455055	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2913055	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1912771	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	659669	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1912771	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	659669	usd
CY2023	rgc	Deferred Tax Assets Addition DeferredTaxAssetsAddition	1000284	usd
CY2022	rgc	Deferred Tax Assets Addition DeferredTaxAssetsAddition	1253102	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2913055	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1912771	usd
CY2023Q2	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	14000000	usd
CY2022Q2	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	9000000	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13012866	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13012866	shares
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On May 31, 2021, the board of directors approved a share split of the Company’s authorized number of Ordinary Shares at a ratio of 1,000-for-1.
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	325000	shares
CY2021Q1	rgc	Promissory Note Principal Amount PromissoryNotePrincipalAmount	3250000	usd
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	342105	shares
CY2021Q3	rgc	Ordinary Shares Par Value OrdinarySharesParValue	9.5
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The Board authorized that the maximum aggregate number of ordinary shares reserved and available pursuant to this Plan shall be the aggregate of (i) 1,235,076 Ordinary Shares, and (ii) on each January 1, starting with January 1, 2022, an additional number of shares equal to the lesser of (A) 2% of the outstanding number of Ordinary Shares (on a fully-diluted basis) on the immediately preceding December 31, and (B) such lower number of Ordinary Shares as may be determined by the board of directors.
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1235076	shares
CY2021Q2	rgc	Option Granted To Director OptionGrantedToDirector	46755	shares
CY2021Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	9.5
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	451084	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	747426	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	438263	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	15585	shares
CY2022Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	31.85
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1235076	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.5
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.45
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y18D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15585	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	31.85
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.84
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	275327	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.5
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	5.45
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	975334	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.86
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.45
CY2022	rgc	Weighted Average Remaining Contractual Term Outstanding Ending WeightedAverageRemainingContractualTermOutstandingEnding	P9Y21D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	24137435	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	175326	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	5.45
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	800008	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.94
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.81
CY2023	rgc	Weighted Average Remaining Contractual Term Outstanding Ending WeightedAverageRemainingContractualTermOutstandingEnding	P8Y21D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10608693	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	922623	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2757907	usd
CY2023	rgc	Public Offering Warrants Description PublicOfferingWarrantsDescription	In connection with and upon closing of the Public Offering and overallotment on July 20, 2021 and August 19, 2021 respectively, the Company issued warrants equal to 2.5% of the shares issued in the Public Offering, totaling 57,500 units and 8,125 units to the placement agents for the offering (the “Public Offering Warrants”). The warrants carry a term of five years, and shall not be exercisable for a period of 180 days from the closing of the Public Offering and shall be exercisable at a price equal to $10.45 per share.
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	270000	usd
CY2021Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	9.27
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0068	pure
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.45
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6524	pure
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	30000.00	usd
CY2021Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6.3
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0077	pure
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.45
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8266	pure
CY2022	rgc	Number Of Warrants Issued NumberOfWarrantsIssued	65625	shares
CY2022	rgc	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	10.45
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	45761	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.45
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	19864	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.45
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	470564	usd
CY2019Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2023	rgc	Lease Payments For Asset Percentage LeasePaymentsForAssetPercentage	0.05	pure
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	410987	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25406	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	360268	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	463669	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	771255	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M25D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	451384	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	24972	usd
CY2023Q2	rgc	Lease Total Minimum Lease Payments LeaseTotalMinimumLeasePayments	476356	usd
CY2023Q2	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	12687	usd
CY2023Q2	us-gaap	Present Value Of Future Minimum Lease Payments Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions	463669	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest		usd
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10000000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12805707	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13012866	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2021	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities		usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	rgc	Conversion Of Shareholder Loan To Convertible Note Payable Related Party ConversionOfShareholderLoanToConvertibleNotePayableRelatedParty		usd
CY2022	rgc	Conversion Of Shareholder Loan To Convertible Note Payable Related Party ConversionOfShareholderLoanToConvertibleNotePayableRelatedParty		usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023	rgc	Deferred Ipo Costs Transferred To Additional Paidin Capital DeferredIPOCostsTransferredToAdditionalPaidinCapital		usd
CY2021	rgc	Deferred Ipo Costs Transferred To Additional Paidin Capital DeferredIPOCostsTransferredToAdditionalPaidinCapital		usd
CY2021	rgc	Rightofuse Assets Obtained In Exchange Of Lease Liabilities RightofuseAssetsObtainedInExchangeOfLeaseLiabilities		usd
CY2022	rgc	Early Termination Of Rightofuse Assets In Exchange Of Lease Liabilities EarlyTerminationOfRightofuseAssetsInExchangeOfLeaseLiabilities		usd
CY2021	rgc	Early Termination Of Rightofuse Assets In Exchange Of Lease Liabilities EarlyTerminationOfRightofuseAssetsInExchangeOfLeaseLiabilities		usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense		usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount		usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount		usd
CY2023	us-gaap	Payments For Rent PaymentsForRent		usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent		usd
CY2022	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022	rgc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted
CY2022	rgc	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValueGranted		usd
CY2022	rgc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Term Expired Forfeited Or Cancelled SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermExpiredForfeitedOrCancelled
CY2022	rgc	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Aggregate Intrinsic Value Expired Forfeited Or Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValueExpiredForfeitedOrCancelled		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	rgc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermGranted
CY2023	rgc	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValueGranted		usd
CY2023	rgc	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Term Expired Forfeited Or Cancelled SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermExpiredForfeitedOrCancelled
CY2023	rgc	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Aggregate Intrinsic Value Expired Forfeited Or Cancelled ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAggregateIntrinsicValueExpiredForfeitedOrCancelled		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
CY2023Q2	rgc	Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Grantdate Fair Value Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageGrantdateFairValueExercisable
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber		shares
CY2021Q2	rgc	Weighted Average Exercise Price Outstanding Per Share WeightedAverageExercisePriceOutstandingPerShare
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber		shares
CY2022Q2	rgc	Weighted Average Exercise Price Outstanding Per Share WeightedAverageExercisePriceOutstandingPerShare
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	0000
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001829667

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
rgc-20230630_cal.xml	Edgar Link	unprocessable
0001013762-23-007289-index-headers.html	Edgar Link	pending
0001013762-23-007289-index.html	Edgar Link	pending
0001013762-23-007289.txt	Edgar Link	pending
0001013762-23-007289-xbrl.zip	Edgar Link	pending
f20f2023ex12-1_regencellbio.htm	Edgar Link	pending
f20f2023ex12-2_regencellbio.htm	Edgar Link	pending
f20f2023ex13-1_regencellbio.htm	Edgar Link	pending
f20f2023ex13-2_regencellbio.htm	Edgar Link	pending
f20f2023ex4-6_regencellbio.htm	Edgar Link	pending
f20f2023ex8-1_regencellbio.htm	Edgar Link	pending
f20f2023_regencellbio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
f20f2023_regencellbio_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgc-20230630.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rgc-20230630_def.xml	Edgar Link	unprocessable
rgc-20230630_lab.xml	Edgar Link	unprocessable
rgc-20230630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGC
Regencell Bioscience Holdings Ltd Stock $rgc

2023 Q2 Form 20-F Financial Statement

#000101376223007289 Filed on October 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGC Regencell Bioscience Holdings Ltd Stock $rgc

2023 Q2 Form 20-F Financial Statement

#000101376223007289 Filed on October 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGC
Regencell Bioscience Holdings Ltd Stock $rgc